The investment seeks to track the investment results (before fees and expenses) of the S&P SmallCap 600® Capped Health Care Index. The fund generally will invest at least 90% of its total assets in the securities that comprise the index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices, LLC compiles, maintains and calculates the index, which is designed to measure the performance of securities of small-capitalization U.S. companies in the health care sector, as defined by the Global Industry Classification Standard.
IPO Year: n/a
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|
Coya Therapeutics Inc (NASDAQ:COYA) is a clinical-stage biotechnology company developing treatments focused on regulatory T cells (Tregs) to target systemic inflammation and neuroinflammation. Since its IPO in December 2022, Coya shares have surged around 70%, significantly outperforming the Invesco S&P SmallCap Health Care ETF (NASDAQ:PSCH). Howard Berman, Chairman and CEO of Coya Therapeutics, sat down with Benzinga this week to share updates on his company’s projects and insights into the industry. Berman had also appeared on Benzinga’s All Access in February. In the Q&A session, Berman pointed out that many biotech companies concentrate on a single neurodegenerative disease
Fortrea Holdings Inc. (NASDAQ:FTRE) shares are trading lower after the company reported soft first-quarter FY24 results and cut its revenue outlook. Revenue of $662.1 million missed the consensus of $754.6 million. As of March-end, the backlog stood at $7.4 billion, and the book-to-bill ratio for the quarter was 1.11x. Adjusted EBITDA stood at $29.5 million, a decline from $41.7 million a year ago. Adjusted EPS of $(0.04) missed the street view of $0.01. In the quarter, operating cash flow came in at $(25.6) million, and free cash flow was $(34.9) million. As of March-end, cash and cash equivalents stood at $92.8 million, and gross debt was $1.65 billion. Tom Pike, chairman and C
Organon & Co (NYSE:OGN) reported a 5% Y/Y increase in the first quarter of 2024 revenue, reaching around $1.622 billion, beating the consensus of $1.563 billion. Women’s Health revenue increased by 11% as reported and 12% ex-FX, driven by 34% ex-FX growth in Nexplanon led by favorable customer purchasing patterns associated with the timing of U.S. list-price adjustments, coupled with favorable price and discount rates in the U.S. and the favorable timing of tenders to markets outside of the U.S. Biosimilar revenue surged by 46% reported and ex-FX, aided by Ontruzant, which benefited from incremental demand from a tender in Brazil and Renflexis, which gained from continued demand growth